Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy

BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is currently classified into ‘typical’ CIDP and ‘atypical’ subtypes such as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM).ObjectivesTo assess the frequency of CIDP subtypes, and to elucidate clinical and ele...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2015-10, Vol.86 (10), p.1054-1059
Hauptverfasser: Kuwabara, Satoshi, Isose, Sagiri, Mori, Masahiro, Mitsuma, Satsuki, Sawai, Setsu, Beppu, Minako, Sekiguchi, Yukari, Misawa, Sonoko
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1059
container_issue 10
container_start_page 1054
container_title Journal of neurology, neurosurgery and psychiatry
container_volume 86
creator Kuwabara, Satoshi
Isose, Sagiri
Mori, Masahiro
Mitsuma, Satsuki
Sawai, Setsu
Beppu, Minako
Sekiguchi, Yukari
Misawa, Sonoko
description BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is currently classified into ‘typical’ CIDP and ‘atypical’ subtypes such as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM).ObjectivesTo assess the frequency of CIDP subtypes, and to elucidate clinical and electrophysiological features, and treatment response in each subtype.MethodsWe reviewed data from 100 consecutive patients fulfilling criteria for CIDP proposed by the European Federation of Neurological Societies and the Peripheral Nerve Society. The Kaplan-Meier curve was used to estimate long-term outcome.ResultsPatients were classified as having typical CIDP (60%), MADSAM (34%), demyelinating acquired distal symmetric neuropathy (8%) or pure sensory CIDP (1%). Compared with patients with MADSAM, patients with typical CIDP showed more rapid progression and severe disability, and demyelination predominant in the distal nerve segments. MADSAM was characterised by multifocal demyelination in the nerve trunks. Abnormal median-normal sural sensory responses were more frequently found for typical CIDP (53% vs 13%). Patients with typical CIDP invariably responded to corticosteroids, immunoglobulin or plasmapheresis, whereas patients with MADSAM were more refractory to these treatments. The Kaplan-Meier analyses showed that 64% of patients with typical CIDP and 41% of patients with MADSAM had a clinical remission 5 years later (p=0.02).ConclusionsAmong the CIDP spectrum, typical CIDP and MADSAM are the major subtypes, and their pathophysiology appears to be distinct. In typical CIDP, the distal nerve terminals and possibly the nerve roots, where the blood–nerve barrier is anatomically deficient, are preferentially affected, raising the possibility of antibody-mediated demyelination, whereas cellular immunity with breakdown of the barrier may be important in MADSAM neuropathy.
doi_str_mv 10.1136/jnnp-2014-308452
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808708658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4023953781</sourcerecordid><originalsourceid>FETCH-LOGICAL-b462t-26dd9e1f600af69190c2e92ec190e81277de0987e721adbb23d4586ea5d335263</originalsourceid><addsrcrecordid>eNqFkU2L1TAUhoMoznV070oKbgSp5rvpUuZDhQE3Cu5K2pzOzSVNapIuupsf4UL_3vwSU-8o4maySTh5zns4PAg9J_gNIUy-PXg_1xQTXjOsuKAP0I5wqWrG8NeHaIcxpeVH4BP0JKUD3o5qH6MTKjjlnIkd-n5uxxEi-FyBgyHHMO_XZIML13bQrppjGK2DVGlvqhxB52ljI6Q5-ASV9dXtzY-8zht9e_PzN1cq-p_SsI_B26Gwo9PTpHOIa2VgWsFZr7P119Uc3OphKdN13q9P0aNRuwTP7u5T9OXy4vPZh_rq0_uPZ--u6p5LmmsqjWmBjBJjPcqWtHig0FIYygsUoU1jALeqgYYSbfqeMsOFkqCFYUxQyU7Rq2Nu2fLbAil3k00DOKc9hCV1RGHVYCWFuh9ttnmNIKKgL_9DD2GJvixSKEUYp4qxQuEjNcSQUoSxm6OddFw7grtNbrfJ7Ta53VFuaXlxF7z0E5i_DX9sFuD1Eeinw_1xvwBjhbTb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781342833</pqid></control><display><type>article</type><title>Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Kuwabara, Satoshi ; Isose, Sagiri ; Mori, Masahiro ; Mitsuma, Satsuki ; Sawai, Setsu ; Beppu, Minako ; Sekiguchi, Yukari ; Misawa, Sonoko</creator><creatorcontrib>Kuwabara, Satoshi ; Isose, Sagiri ; Mori, Masahiro ; Mitsuma, Satsuki ; Sawai, Setsu ; Beppu, Minako ; Sekiguchi, Yukari ; Misawa, Sonoko</creatorcontrib><description>BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is currently classified into ‘typical’ CIDP and ‘atypical’ subtypes such as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM).ObjectivesTo assess the frequency of CIDP subtypes, and to elucidate clinical and electrophysiological features, and treatment response in each subtype.MethodsWe reviewed data from 100 consecutive patients fulfilling criteria for CIDP proposed by the European Federation of Neurological Societies and the Peripheral Nerve Society. The Kaplan-Meier curve was used to estimate long-term outcome.ResultsPatients were classified as having typical CIDP (60%), MADSAM (34%), demyelinating acquired distal symmetric neuropathy (8%) or pure sensory CIDP (1%). Compared with patients with MADSAM, patients with typical CIDP showed more rapid progression and severe disability, and demyelination predominant in the distal nerve segments. MADSAM was characterised by multifocal demyelination in the nerve trunks. Abnormal median-normal sural sensory responses were more frequently found for typical CIDP (53% vs 13%). Patients with typical CIDP invariably responded to corticosteroids, immunoglobulin or plasmapheresis, whereas patients with MADSAM were more refractory to these treatments. The Kaplan-Meier analyses showed that 64% of patients with typical CIDP and 41% of patients with MADSAM had a clinical remission 5 years later (p=0.02).ConclusionsAmong the CIDP spectrum, typical CIDP and MADSAM are the major subtypes, and their pathophysiology appears to be distinct. In typical CIDP, the distal nerve terminals and possibly the nerve roots, where the blood–nerve barrier is anatomically deficient, are preferentially affected, raising the possibility of antibody-mediated demyelination, whereas cellular immunity with breakdown of the barrier may be important in MADSAM neuropathy.</description><identifier>ISSN: 0022-3050</identifier><identifier>EISSN: 1468-330X</identifier><identifier>DOI: 10.1136/jnnp-2014-308452</identifier><identifier>PMID: 25424435</identifier><identifier>CODEN: JNNPAU</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Adult ; Apheresis ; Female ; Follow-Up Studies ; Glycoproteins ; Guillain-Barre syndrome ; Humans ; Immunoglobulins ; Immunoglobulins, Intravenous - therapeutic use ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neural Conduction ; Pathophysiology ; Patients ; Plasmapheresis ; Polyradiculoneuropathy - physiopathology ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - therapy ; Prognosis ; Steroids ; Sural Nerve - physiopathology ; Treatment Outcome</subject><ispartof>Journal of neurology, neurosurgery and psychiatry, 2015-10, Vol.86 (10), p.1054-1059</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b462t-26dd9e1f600af69190c2e92ec190e81277de0987e721adbb23d4586ea5d335263</citedby><cites>FETCH-LOGICAL-b462t-26dd9e1f600af69190c2e92ec190e81277de0987e721adbb23d4586ea5d335263</cites><orcidid>0000-0002-4716-8578</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jnnp.bmj.com/content/86/10/1054.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jnnp.bmj.com/content/86/10/1054.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25424435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuwabara, Satoshi</creatorcontrib><creatorcontrib>Isose, Sagiri</creatorcontrib><creatorcontrib>Mori, Masahiro</creatorcontrib><creatorcontrib>Mitsuma, Satsuki</creatorcontrib><creatorcontrib>Sawai, Setsu</creatorcontrib><creatorcontrib>Beppu, Minako</creatorcontrib><creatorcontrib>Sekiguchi, Yukari</creatorcontrib><creatorcontrib>Misawa, Sonoko</creatorcontrib><title>Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy</title><title>Journal of neurology, neurosurgery and psychiatry</title><addtitle>J Neurol Neurosurg Psychiatry</addtitle><description>BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is currently classified into ‘typical’ CIDP and ‘atypical’ subtypes such as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM).ObjectivesTo assess the frequency of CIDP subtypes, and to elucidate clinical and electrophysiological features, and treatment response in each subtype.MethodsWe reviewed data from 100 consecutive patients fulfilling criteria for CIDP proposed by the European Federation of Neurological Societies and the Peripheral Nerve Society. The Kaplan-Meier curve was used to estimate long-term outcome.ResultsPatients were classified as having typical CIDP (60%), MADSAM (34%), demyelinating acquired distal symmetric neuropathy (8%) or pure sensory CIDP (1%). Compared with patients with MADSAM, patients with typical CIDP showed more rapid progression and severe disability, and demyelination predominant in the distal nerve segments. MADSAM was characterised by multifocal demyelination in the nerve trunks. Abnormal median-normal sural sensory responses were more frequently found for typical CIDP (53% vs 13%). Patients with typical CIDP invariably responded to corticosteroids, immunoglobulin or plasmapheresis, whereas patients with MADSAM were more refractory to these treatments. The Kaplan-Meier analyses showed that 64% of patients with typical CIDP and 41% of patients with MADSAM had a clinical remission 5 years later (p=0.02).ConclusionsAmong the CIDP spectrum, typical CIDP and MADSAM are the major subtypes, and their pathophysiology appears to be distinct. In typical CIDP, the distal nerve terminals and possibly the nerve roots, where the blood–nerve barrier is anatomically deficient, are preferentially affected, raising the possibility of antibody-mediated demyelination, whereas cellular immunity with breakdown of the barrier may be important in MADSAM neuropathy.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Apheresis</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glycoproteins</subject><subject>Guillain-Barre syndrome</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neural Conduction</subject><subject>Pathophysiology</subject><subject>Patients</subject><subject>Plasmapheresis</subject><subject>Polyradiculoneuropathy - physiopathology</subject><subject>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology</subject><subject>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - therapy</subject><subject>Prognosis</subject><subject>Steroids</subject><subject>Sural Nerve - physiopathology</subject><subject>Treatment Outcome</subject><issn>0022-3050</issn><issn>1468-330X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkU2L1TAUhoMoznV070oKbgSp5rvpUuZDhQE3Cu5K2pzOzSVNapIuupsf4UL_3vwSU-8o4maySTh5zns4PAg9J_gNIUy-PXg_1xQTXjOsuKAP0I5wqWrG8NeHaIcxpeVH4BP0JKUD3o5qH6MTKjjlnIkd-n5uxxEi-FyBgyHHMO_XZIML13bQrppjGK2DVGlvqhxB52ljI6Q5-ASV9dXtzY-8zht9e_PzN1cq-p_SsI_B26Gwo9PTpHOIa2VgWsFZr7P119Uc3OphKdN13q9P0aNRuwTP7u5T9OXy4vPZh_rq0_uPZ--u6p5LmmsqjWmBjBJjPcqWtHig0FIYygsUoU1jALeqgYYSbfqeMsOFkqCFYUxQyU7Rq2Nu2fLbAil3k00DOKc9hCV1RGHVYCWFuh9ttnmNIKKgL_9DD2GJvixSKEUYp4qxQuEjNcSQUoSxm6OddFw7grtNbrfJ7Ta53VFuaXlxF7z0E5i_DX9sFuD1Eeinw_1xvwBjhbTb</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Kuwabara, Satoshi</creator><creator>Isose, Sagiri</creator><creator>Mori, Masahiro</creator><creator>Mitsuma, Satsuki</creator><creator>Sawai, Setsu</creator><creator>Beppu, Minako</creator><creator>Sekiguchi, Yukari</creator><creator>Misawa, Sonoko</creator><general>BMJ Publishing Group LTD</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><orcidid>https://orcid.org/0000-0002-4716-8578</orcidid></search><sort><creationdate>20151001</creationdate><title>Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy</title><author>Kuwabara, Satoshi ; Isose, Sagiri ; Mori, Masahiro ; Mitsuma, Satsuki ; Sawai, Setsu ; Beppu, Minako ; Sekiguchi, Yukari ; Misawa, Sonoko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b462t-26dd9e1f600af69190c2e92ec190e81277de0987e721adbb23d4586ea5d335263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Apheresis</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glycoproteins</topic><topic>Guillain-Barre syndrome</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neural Conduction</topic><topic>Pathophysiology</topic><topic>Patients</topic><topic>Plasmapheresis</topic><topic>Polyradiculoneuropathy - physiopathology</topic><topic>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology</topic><topic>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - therapy</topic><topic>Prognosis</topic><topic>Steroids</topic><topic>Sural Nerve - physiopathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuwabara, Satoshi</creatorcontrib><creatorcontrib>Isose, Sagiri</creatorcontrib><creatorcontrib>Mori, Masahiro</creatorcontrib><creatorcontrib>Mitsuma, Satsuki</creatorcontrib><creatorcontrib>Sawai, Setsu</creatorcontrib><creatorcontrib>Beppu, Minako</creatorcontrib><creatorcontrib>Sekiguchi, Yukari</creatorcontrib><creatorcontrib>Misawa, Sonoko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuwabara, Satoshi</au><au>Isose, Sagiri</au><au>Mori, Masahiro</au><au>Mitsuma, Satsuki</au><au>Sawai, Setsu</au><au>Beppu, Minako</au><au>Sekiguchi, Yukari</au><au>Misawa, Sonoko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy</atitle><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>86</volume><issue>10</issue><spage>1054</spage><epage>1059</epage><pages>1054-1059</pages><issn>0022-3050</issn><eissn>1468-330X</eissn><coden>JNNPAU</coden><abstract>BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is currently classified into ‘typical’ CIDP and ‘atypical’ subtypes such as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM).ObjectivesTo assess the frequency of CIDP subtypes, and to elucidate clinical and electrophysiological features, and treatment response in each subtype.MethodsWe reviewed data from 100 consecutive patients fulfilling criteria for CIDP proposed by the European Federation of Neurological Societies and the Peripheral Nerve Society. The Kaplan-Meier curve was used to estimate long-term outcome.ResultsPatients were classified as having typical CIDP (60%), MADSAM (34%), demyelinating acquired distal symmetric neuropathy (8%) or pure sensory CIDP (1%). Compared with patients with MADSAM, patients with typical CIDP showed more rapid progression and severe disability, and demyelination predominant in the distal nerve segments. MADSAM was characterised by multifocal demyelination in the nerve trunks. Abnormal median-normal sural sensory responses were more frequently found for typical CIDP (53% vs 13%). Patients with typical CIDP invariably responded to corticosteroids, immunoglobulin or plasmapheresis, whereas patients with MADSAM were more refractory to these treatments. The Kaplan-Meier analyses showed that 64% of patients with typical CIDP and 41% of patients with MADSAM had a clinical remission 5 years later (p=0.02).ConclusionsAmong the CIDP spectrum, typical CIDP and MADSAM are the major subtypes, and their pathophysiology appears to be distinct. In typical CIDP, the distal nerve terminals and possibly the nerve roots, where the blood–nerve barrier is anatomically deficient, are preferentially affected, raising the possibility of antibody-mediated demyelination, whereas cellular immunity with breakdown of the barrier may be important in MADSAM neuropathy.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>25424435</pmid><doi>10.1136/jnnp-2014-308452</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4716-8578</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-3050
ispartof Journal of neurology, neurosurgery and psychiatry, 2015-10, Vol.86 (10), p.1054-1059
issn 0022-3050
1468-330X
language eng
recordid cdi_proquest_miscellaneous_1808708658
source MEDLINE; BMJ Journals - NESLi2
subjects Adrenal Cortex Hormones - therapeutic use
Adult
Apheresis
Female
Follow-Up Studies
Glycoproteins
Guillain-Barre syndrome
Humans
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Kaplan-Meier Estimate
Male
Middle Aged
Neural Conduction
Pathophysiology
Patients
Plasmapheresis
Polyradiculoneuropathy - physiopathology
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - therapy
Prognosis
Steroids
Sural Nerve - physiopathology
Treatment Outcome
title Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A39%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20electrophysiological%20profiles%20and%20treatment%20response%20in%20%E2%80%98typical%E2%80%99%20and%20%E2%80%98atypical%E2%80%99%20chronic%20inflammatory%20demyelinating%20polyneuropathy&rft.jtitle=Journal%20of%20neurology,%20neurosurgery%20and%20psychiatry&rft.au=Kuwabara,%20Satoshi&rft.date=2015-10-01&rft.volume=86&rft.issue=10&rft.spage=1054&rft.epage=1059&rft.pages=1054-1059&rft.issn=0022-3050&rft.eissn=1468-330X&rft.coden=JNNPAU&rft_id=info:doi/10.1136/jnnp-2014-308452&rft_dat=%3Cproquest_cross%3E4023953781%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781342833&rft_id=info:pmid/25424435&rfr_iscdi=true